JGC
SIOX

J. Goldman & Co’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

J. Goldman & Co’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-120,000
Closed -$334K – 558
2020
Q4 		$334K Buy
+120,000
New +$349K 0.02% 303
2017
Q4 		– Sell
-3,250
Closed -$179K – 465
2017
Q3 		$179K Buy
+3,250
New +$548K 0.01% 313

Other funds holding SIOX

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TVWM
Tower View Wealth Management Shorewood, Wisconsin $227M AUM 41.04% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

J. Goldman & Co's SIOX Position: Q1 2021 in Review

J. Goldman & Co sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2021, closing a stake of 126,160 shares — an estimated $351K sold.

J. Goldman & Co first reported a position in SIOX in Q3 2016 and held it in 5 quarters. The position peaked at $1.99M in Q3 2016. 56 funds tracked by Wall St. Rank hold SIOX as of Q1 2021.

  • J. Goldman & Co reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • J. Goldman & Co sold 126,160 Sio Gene Therapies Inc. Common Stock shares in Q1 2021, an estimated $351K.
  • J. Goldman & Co first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2016 and held it in 5 quarters.
  • J. Goldman & Co's Sio Gene Therapies Inc. Common Stock position peaked at $1.99M in Q3 2016.
  • 56 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2021.

Based on J. Goldman & Co's 13F filing for Q1 2021, filed 17 May 2021.